Implantable medical devices that come into contact with flowing blood are widely used in clinical practice. Some, such as artificial heart valves, vascular grafts, ventricular assist devices (VADs), extracorporeal membrane oxygenation (ECMO) circuits, and central venous lines may be exposed to blood for months to years, while others including extracorporeal circuits used in hemodialysis and cardiopulmonary bypass (CPB) are exposed for shorter durations. Despite advances in development of biocompatible materials, most implantable devices induce blood clot formation that may lead to their failure or to thromboembolic sequelae. [1] [2] [3] The device surfaces exposed to blood lack the endothelial cell layer that actively retards coagulation and platelet adhesion in normal blood vessels, and anticoagulation and/or antiplatelet therapy is required to prevent thrombus formation. Plasma proteins rapidly adsorb onto most nonbiologic materials, forming a layer several nanometers thick in which protein concentrations are several orders of magnitude higher than in circulating blood. 3, 4 Initially, abundant proteins such as albumin and fibrinogen deposit on the surface. Fibrinogen, with other adhesive proteins such as von Willebrand factor and fibronectin, anchors platelets and other blood cells to the surface. With time, the types of adherent proteins change, a process called the Vroman effect. [5] [6] [7] [8] Fibrinogen is replaced by surface recognition proteins involved in the innate immune response, including components of the complement system and the contact factors. The plasma contact factors are factor XII (FXII), plasma prekallikrein (PPK), and factor XI (FXI), the precursors of the proteases α-FXIIa, α-kallikrein (P-Kal), and FXIa, respectively, and the nonenzyme glycoprotein high-molecular-weight kininogen (HK) (►Fig. 1). [9] [10] [11] Assembly of the contact system on surfaces enhances several host-defense processes including kinin generation, complement activation and thrombin generation, promoting inflammation and coagulation (►Fig. 2).
and P-Kal) or serve a relatively minor role (FXIa), in the normal hemostatic response to blood vessel injury, it is anticipated that drugs targeting them would cause fewer bleeding complications than currently used anticoagulants. Given the presumed importance of contact factors to surface-induced coagulation, they may be ideal targets for prevention of thrombus formation on surfaces of medical devices. In this review, we discuss the role of contact activation in thrombosis associated with implantable devices and the preclinical data supporting FXII or FXI as targets for preventing device-induced thrombosis. 
Contact Activation and Blood Coagulation
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FXIIa and P-Kal may contribute to several homeostatic and host-defense processes. P-Kal cleaves HK (►Fig. 2, reaction 4), releasing the proinflammatory peptide bradykinin (►Fig. 1). When plasma is exposed to a surface, the contact activation reactions shown in ►Fig. 2 lead to accumulation of FXIa (red arrows). FXIa converts factor IX to factor IXaβ in a calcium-dependent manner (green arrow). Factor IXaβ converts factor X to factor Xa in a calcium/phospholipid-dependent reaction requiring the cofactor factor VIIIa, and factor Xa in terms convers prothrombin (factor II) to thrombin (factor IIa) in the presence of the cofactor Va, phospholipid, and calcium. Thrombin catalyzes multiple reactions, including fibrinogen conversion to fibrin and platelet activation through cleavage of protease activated receptors 1 and 4. The reactions depicted are required for normal coagulation in vitro in aPTT assays. aPTT, activated partial thromboplastin time; FXI, factor XI.
bleeding diathesis associated with FXI deficiency is relatively mild when compared with deficiency of its substrate factor IX, 18 pointing to an ancillary role for FXI in hemostasis.
However, despite its minor contribution to hemostasis, mounting evidence suggests FXI and contact activation make substantive contributions to thrombosis.
Contact Activation and Thrombosis in Animal Models
In most in vivo thrombosis models, vessel occlusion is a rapid event induced in a healthy animal by acute injury (mechanical, chemical, photon) to a normal blood vessel, infusion of prothrombotic material (tissue factor, polyphosphate) into a vessel, or placement of a device (vascular graft, venous catheter, wire, thread) within a vessel. Although it is questionable whether such models accurately reflect processes involved in human venous thromboembolism (VTE), stroke, or myocardial infarction (MI), some may be relevant for surface-induced coagulation associated with implantable medical devices. The contact factors contribute to venous and arterial occlusion in animals. 10, 15, 26, 45 Studies with mice lacking components of the contact system are illustrative. FXI and FXII deficient mice are as resistant to injury-induced thrombosis as are factor IX-deficient mice (a model of the hemorrhagic disorder hemophilia B). 26, [46] [47] [48] [49] Mice lacking PPK or HK are also resistant to thrombus formation, consistent with a role for contact activation in thrombosis. [49] [50] [51] [52] [53] In addition, PPK-deficient mice have reduced levels of tissue factor and higher levels of prostacyclin in their blood vessels than wild-type mice, perhaps due to reduced bradykinin generation. 51 This suggests that chronic suppression of contact activation could produce therapeutic effects by thrombin-dependent and thrombin-independent mechanisms. The possibility that thrombotic processes in mice differ from those in primates is an important issue. When collagencoated vascular grafts are placed within temporary arteriovenous fistulas in baboons, platelets and fibrin deposit in the grafts.
10,54 Inhibition of FXI or FXII reduces thrombus growth, 45, [54] [55] [56] but in contrast to thrombus formation in mice, FXI inhibition in baboons limits thrombus formation to a greater extent than does FXII inhibition. 10,54-56 These results suggest that FXI activation by FXII-independent processes is more important for thrombosis in primates than mice, and they imply that FXI may be a better antithrombotic target in humans. This premise is in line with data for VTE, stroke, and MI in humans, as discussed later.
Contact Activation and Thrombosis in Humans
There is a considerable body of work linking FXI to thrombosis in humans. The process is initiated at a wound site by the factor VIIa/ complex, which converts factor X to factor Xa. Factor Xa in turn initiates prothrombin conversion (factor II) to thrombin (factor IIa). Factor VIIa/TF also converts factor IX to factor IXaβ, which sustains factor X activation. In some situations, additional factor IX activation through FXIa is required for hemostasis. It is thought that FXI activation in these cases is through a reaction that does not involve FXII. In the diagram, thrombin is shown activating FXI (gray arrow with dashed borders). The gray box displays the contact activation reactions shown in ►Fig. 
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It seems reasonable to conclude that FXII contributes less to VTE and stroke, and perhaps MI, than does FXI. This in turn suggests that FXI activation via FXII-independent processes is more important than contact activation in these disorders, consistent with the impression that tissue factor-initiated thrombin generation is a major driver of thrombosis in humans. 74, 75 Further support for the conclusion that FXII makes relatively small contributions to VTE, stroke, and MI come from observations of patient lacking C1-inhibitor (C1-INH), the major regulator of FXIIa and P-Kal. Congenital C1-INH deficiency causes hereditary angioedema (HAE), a disorder associated with activation of the contact system and bouts of soft tissue swelling due to excessive bradykinin generation. largely responsible for thrombin generation in this setting. The discrepant data could reflect differences in assay sensitivities, or differences in oxygenator surfaces or protocols used in different places at different times. It is also important to keep in mind that the high heparin concentrations used in CPB may blunt contact activation. Observations that patients with FXII deficiency still have evidence of increased thrombin generation during CPB have been used to argue against a role for contact activation in CPB-induced coagulation. 94 Although the observation is consistent with tissue factor-induced thrombin production, this process must occur in patients undergoing surgery to prevent exsanguination. It does not necessarily follow that tissue factor-dependent thrombin generation is responsible for thrombosis in CPB. There is limited data for ECMO, a procedure that uses lower heparin concentrations than in CPB. Using ex vivo ECMO circuits, Wendel et al observed higher FXIIa and P-Kal levels in blood passing through nonheparin-coated circuits than heparin-coated circuits, 95 heparin. In ex vivo studies of renal dialysis circuits, Frank et al observed thrombin generation (detected by measuring TAT complexes) when normal blood is exposed to different types of dialysis membranes. 82 The most thrombogenic membrane (AN69XT Nephral 200) increased TAT in a FXII-dependent manner, with FXIIa-C1-INH complexes accumulating in normal blood exposed to the membrane. VADs are becoming a common option for patients with advanced heart failure, either as a bridge to cardiac transplantation or as destination therapy. With these devices, blood is exposed to relatively small metal surfaces rather than large surface area membranes, and antithrombotic regimens are based primarily on warfarin and antiplatelet agents, which are unlikely to affect contact activation. Studies in animals and humans show reductions in plasma levels of FXII, FXI, PPK, and HK after VAD placement, [96] [97] [98] [99] [100] with increased levels of the activated forms of these proteins. 101 FXII autoactivation and reciprocal FXII-PPK activation occurs in the protein layer adherent to the titanium-alloy surface of the devices.
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It is not clear if the surface promotes true contact activation through induction of conformational changes to surfacebound proteins, as in aPTT assays, or simply facilitates enzymatic reactions by concentrating proteins on the surface. In summary, while some data from human patients point to a role for contact activation as a contributor to implantable device-induced thromboinflammation, others do not. In our opinion, a major limiting factor in these studies is the use of anticoagulants such as heparin that inhibit the very processes under study. Animal models are probably better suited for addressing this issue, as studies can include nontreatment control arms.
Preclinical Studies Targeting FXII and FXI for Thromboprophylaxis with Medical Device
Several compelling studies have been published in recent years that convincingly implicate the contact system in implantable device-induced thrombosis in animal models. These studies have provided proof of concept for testing inhibitors of FXII and FXI in humans. Larsson et al studied the effects of therapeutic FXIIa inhibition in rabbits connected to pediatric ECMO circuits. 104, 105 In the absence of an anticoagulant, the circuit rapidly occluded with heavy deposition of fibrin on the surface of the oxygenator elements. Treating the animals with unfractionated heparin, as expected, prevented circuit occlusion. Animals on heparin demonstrated significant bleeding with injury to the skin or cuticle, consistent with the known effects of this drug on factor Xa and thrombin. Treatment with a monoclonal immunoglobulin G (IgG) (3F7) that specifically recognizes the active site of FXIIa prevented fibrin deposition and circuit occlusion, with an effect at least as good as that of heparin. As importantly, 3F7 did not prolong bleeding times in either injury model, despite prolonging the aPTT, consistent with the clinical impression that FXII deficiency does not compromise hemostasis.
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Yau et al studied the effects of factor VII, FXI, FXII, or HK reduction on thrombus formation induced by polyurethane catheters inserted into the jugular veins of rabbits. The protein levels were reduced by 90% using factor-specific antisense oligonucleotides that inhibit production of the proteins in the liver.
106 FXII or FXI reduction prolonged the time to catheter-induced thrombus formation more than twofold, while factor VII or HK reduction had little effect. At first glance, the negative result with HK reduction suggests that a process distinct from classic contact activation may contribute to thrombosis in this model. However, the normal plasma level of HK is > 600 nM and even 10% residual protein may provide enough cofactor activity to support contact activation. Recently, David et al described monoclonal IgGs that specifically block the catalytic activity of FXIa, and tested their ability to prevent jugular vein thrombosis induced by placement of a thrombogenic thread within the lumen of the blood vessel. 107 The antibody DEF prevented vessel occlusion with an efficacy comparable to that of the factor Xa active site inhibitor rivaroxaban. At a concentration 10-fold higher than that required to prevent vessel occlusion, DEF did not increase the cuticle bleeding in rabbits, in contrast to therapeutic doses of rivaroxaban, which caused a significant increase in bleeding. clinical studies, these agents will probably be tested first as primary or secondary thrombosis prophylaxis, rather than treatment of acute thrombotic events. Although the phase 2 trial demonstrating that decreasing FXI level prevents venous thrombus formation in patients undergoing knee arthroplasty is an encouraging start, 62 our understanding of the roles of FXIa and FXIIa in human thrombosis and the types of thrombotic events that may respond to inhibitors of these proteases are incomplete. Among their possible roles, FXIIa and FXIa appear to function as part of the innate host response to infection, assembling and activating on surfaces of microorganisms.
Conclusion and Future Directions
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Given this, it is not surprising that the system would assemble on foreign materials used in implantable medical devices. Prevention of artificial surface-induced thrombosis with FXIIa and FXIa inhibitors seems to be an obvious path to pursue. A major advantage of FXIa or FXIIa inhibition over currently available anticoagulants is likely to be in the area of safety. These proteins serve, at most, supportive roles in hemostasis and, hypothetically, complete inhibition of either should be well tolerated under most circumstances. This could be of great value in certain groups of patients with implantable devices who are prone to excessive bleeding. For example, many patients on ECMO are infants who bleed with heparin therapy even as they are at risk for thromboembolic events. Patients who have undergone VAD implantation develop an acquired von Willebrand syndrome due to mechanical and shear-induced degradation of von Willebrand factor. 109, 110 This defect, superimposed on warfarin and antiplatelet agents used to prevent device-induced thrombosis, leaves these patients Inhibition of Factors XI and XII Tillman, Gailani 65 prone to severe bleeding, particularly from the gastrointestinal tract. Targeted inhibition of FXIa or FXIIa may reduce thrombotic risk in a manner that would leave hemostasis largely intact. These agents could also be combined with standard drugs to reduce the required intensity of the standard therapy. It remains to be established if FXII or FXI is the better target for preventing implantable device-induced thrombosis. Both have potential advantages and disadvantages. For FXII, the fact that it is not required for hemostasis and that it triggers surface-induced coagulation seems to make it an ideal target. Furthermore, FXII inhibition may limit PPK activation, blunting inflammation. Population-based studies raise the possibility that FXII may serve a less important role in thrombosis in humans than does FXI. However, while this may be the case for common disorders such as MI, stroke, and VTE, it does not imply that FXII does not participate substantively in thrombosis on nonbiologic surfaces. Inhibition of FXI, hypothetically, would interfere with contact activation-induced thrombin generation and the thrombin-initiated feedback loop that sustains factor IX activation (►Fig. 4), producing a more potent antithrombotic effect than would inhibition of FXII. Interestingly, recent data also point to a role for FXI in inflammation. [111] [112] [113] Although the cascade/waterfall hypothesis (►Fig. 3) describes FXIa as a product of contact activation, we observed that FXIa stimulates contact activation in vitro and in vivo by enhancing FXII activation. 112 We postulate that FXI is a bidirectional interface connecting thrombin generation and contact activation, as shown in ►Fig. 4, and its inhibition could prevent cross-talk between the two systems. 10 A concern with a FXI inhibitor is bleeding. Indeed, some patients with FXI deficiency do experience excessive trauma or surgery-induced bleeding. 18 However, bleeding is rarely spontaneous in FXI-deficient patients and tends to involve specific tissues. 18 The observation that low FXI levels did not compromise hemostasis in knee replacement surgery 61 suggests FXI inhibition should cause fewer hemorrhagic problems compared with heparin or warfarin. As agents targeting the contact factors become available, we will be able to test individual and combination drug therapies to determine if they will have utility in preventing thrombosis in patients with implantable devices.
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